Investigational drug · Phase 3
HFA-134a
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Asthma.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
105
Any phase or sponsor naming "HFA-134a"
First trial start
2025
Dec 17, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HFA-134a", any sponsor or status.
Conditions studied
As listed on its trial records.
- Asthma
Approved drugs for the same conditions: Asthma · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "HFA-134a" as an intervention, largest first.
Research in Real-Life LtdResearch network
NCT01697722 · 815,377 participants · Start Jan 1991 · Primary completion Jun 2007
Drug: Extra-fine hydrofluoroalkane-beclometasone dipropionate; ICS / LABA via separate pMDI and / or BAI inhalers · For: Asthma
Sites: London, United Kingdom
- Real-life Effectiveness and Cost-effectiveness of Qvar Versus FP and BDP in the Management of COPDCompleted
Research in Real-Life LtdResearch network
NCT01141452 · 815,377 participants · Start Jan 2001 · Primary completion Jun 2007
Drug: Extra-fine hydrofluoroalkane beclomethasone MDI; Chlorofluorocarbon beclomethasone metered dose inhaler and 4 more · For: Chronic Obstructive Pulmonary Disease
Sites: London, United Kingdom
Research in Real-Life LtdResearch network
NCT01141439 · 815,377 participants · Start Jan 2001 · Primary completion Jun 2007
Drug: Extra-fine hydrofluoroalkane-beclomethasone dipropionate; Extra-fine hydrofluoroalkane-beclomethasone dipropionate and 4 more · For: Asthma
Sites: London, United Kingdom
Research in Real-Life LtdResearch network
NCT01287351 · 82,903 participants · Start Jan 2004 · Primary completion Dec 2008
Drug: extra-fine hydrofluoroalkane beclometasone dipropionate; Fluticasone propionate · For: Asthma
Sites: Cawston, United Kingdom
Research in Real-Life LtdResearch network
NCT01400217 · 56,985 participants · Start Jan 1991 · Primary completion Oct 2010
Drug: extra fine particle hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler; standard particle particle hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler · For: Asthma
Sites: Cawston, United Kingdom
- Qvar vs FP in PediatricsCompleted
Research in Real-Life LtdResearch network
NCT01877954 · 2,654 participants · Start Feb 2011 · Primary completion Mar 2013
Drug: Extra-fine hydrofluoroalkane beclometasone dipropionate; Fluticasone propionate · For: Asthma
- A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent AsthmaPivotal-lookingCompleted
Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
NCT02031640 · 1,113 participants · Start Dec 2013 · Primary completion Nov 2014
Drug: Beclomethasone dipropionate; Placebo and 1 more · For: Asthma
Sites: Costa Mesa, California; Huntington Beach, California; Long Beach, California · 131 sites in all
- A 6 Month Safety and Efficacy Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) in the Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and OlderPivotal-lookingCompleted
Sumitomo Pharma America, Inc.Industry
NCT00953147 · 1,110 participants · Start Aug 2009 · Primary completion Jan 2010
Drug: Ciclesonide HFA 80 mcg; Ciclesonide HFA 160 mcg and 1 more · For: Allergic Rhinitis; Perennial Allergic Rhinitis
Sites: Huntington Beach, California; Los Angeles, California; Mission Viejo, California · 45 sites in all
- A Comparative Study of Inhaled Ciclesonide Versus Placebo in Children (6-11 Years) With AsthmaPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00384189 · 1,080 participants · Start Sep 2006 · Primary completion Aug 2007
Drug: Ciclesonide; Placebo and 1 more · For: Asthma
Sites: Plovdiv, Bulgaria; Rousse, Bulgaria; Sofia, Bulgaria · 122 sites in all
Boehringer IngelheimBoehringer Ingelheim
NCT01172808 · 1,071 participants · Start Aug 2010 · Primary completion Nov 2012
Drug: Placebo; tiotropium Respimat® low dose and 6 more · For: Asthma
Sites: Huntington Beach, California; Mission Viejo, California; San Diego, California · 114 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Understanding and controlling the sources of variability in pMDI plume temperature measurements.
Brini R, Hopkins LJ, Copelli D, et al. · Eur J Pharm Sci 2026
- Principles for a patient-centred transition to low-global warming potential pressurised metered-dose inhalers.
Halpin DM, Kaplan A, Field D, et al. · NPJ Prim Care Respir Med 2026
- Pharmacodynamic Equivalence and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate With a Next-Generation Propellant Versus Hydrofluoroalkane-134a Propellant: A Randomized Phase 3 Study in Chronic Obstructive Pulmonary Disease.
Camiolo M, Pandya H, Jassal M, et al. · Chronic Obstr Pulm Dis 2026
- Pharmaceutical assessment of low global warming potential alternatives to HFA-134a in a budesonide, glycopyrrolate, and formoterol fumarate pressurized metered-dose inhaler.
Lachacz K, Kaye R, Mello L, et al. · J Pharm Sci 2026
- Developing low-carbon metered-dose inhalers: effects of propellant HFA-152a on mucociliary clearance and bronchoconstriction in two Phase 1 randomised trials.
Singh D, Poggesi I, Weng S, et al. · Respir Med 2026
- Switching to a Low Global Warming Potential Propellant in a Pressurized Metered-Dose Inhaler Does Not Affect the Pharmacokinetics of Combined Beclometasone Dipropionate/Formoterol Fumarate.
Almeida M, Salvadori M, Corradi M, et al. · Clin Ther 2026
Also in development for Asthma
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- LunsekimigSAR443765Phase 39 trials
Sanofi · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps
- GSK5784283Phase 38 trials
GSK · Pulmonary Disease, Chronic Obstructive, Asthma, Nasal Polyps
- PF-07275315tilrekimigPhase 38 trials
Pfizer · Atopic Dermatitis, Asthma, Moderate to Severe Chronic Obstructive Pulmonary Disease
- MG-K10Humanized Monoclonal AntibodyPhase 36 trials
Shanghai Mabgeek Biotech.Co.Ltd · Dermatitis, Atopic, Chronic Urticaria, Idiopathic, Atopic Dermatitis
- SHR-1905Phase 36 trials
Guangdong Hengrui Pharmaceutical Co., Ltd · Asthma, Chronic Rhinosinusitis With Nasal Polyps, Moderate-to-severe Atopic Dermatitis
- TozorakimabMEDI3506Phase 36 trials
AstraZeneca · Chronic Obstructive Pulmonary Disease (COPD), Asthma, Viral Lung Infection and Acute Respiratory Failure
- TQC2731Phase 35 trials
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from GSK.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.